Daniel R. Chevallard, Chief Financial Officer at Regulus Therapeutics Inc. (RGLS), sold 2,669 shares at $1.31 ($3K) on 2019-07-01, disclosed to the SEC on 2019-07-02.
Scheduled sale ($3k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| LENZ | BUY | 2024-05-15 | $50K | — | Filing → |
| VIRX | SELL | 2024-02-27 | $2K | — | Filing → |
| VIRX | SELL | 2023-11-28 | $2K | — | Filing → |